Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities

Neuropharmacology

Volumn 124, Issue , 2017, Pages 3-12

  Khurana, Leepakshi ^a   Mackie, Ken ^b   Piomelli, Daniele ^c   Kendall, Debra A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allosteric modulator; Biased signaling; CB1; Therapeutic potential

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; GAT 211; GAT 229; LIPOXIN A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ORG 27569; PEPCAN 12; PREGNENOLONE; PSNCBAM 1; RTI 371; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR AFFECTING AGENT; LIGAND;

ALLOSTERISM; BINDING SITE; CALCIUM MOBILIZATION; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG EFFECT; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; CANNABINOID RECEPTOR MODULATORS; HUMANS; LIGANDS; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85019603068     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.05.018     Document Type: Review

References (87)

1. 1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J. Biol. Chem. 287 (2012), 12070–12082.
2. 1). J. Biol. Chem. 288 (2013), 9790–9800.
3. Aso, E., Ferrer, I., Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front. Pharmacol., 5, 2014, 37.
4. Baillie, G.L., Horswill, J.G., Anavi-Goffer, S., Reggio, P.H., Bolognini, D., Abood, M.E., McAllister, S., Strange, P.G., Stephens, G.J., Pertwee, R.G., Ross, R.A., CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol. Pharmacol. 83 (2013), 322–338.
5. 1 receptors. J. Biol. Chem. 287 (2012), 36944–36967.
6. Bellocchio, L., Mancini, G., Vicennati, V., Pasquali, R., Pagotto, U., Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol. 6 (2006), 586–591.
7. Blake, D.R., Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45 (2006), 50–52.
8. 1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3 (2003), 54–61.
9. Bruno, A., Lembo, F., Novellino, E., Stornaiuolo, M., Marinelli, L., Beyond radio-displacement techniques for identification of CB1 ligands: the first application of a fluorescence-quenching assay. Sci. Reps., 4, 2014 3757.
10. Burford, N.T., Watson, J., Bertekap, R., Alt, A., Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem. Pharmacol. 81 (2011), 691–702.
11. Burford, N.T., Clark, M.J., Wehrman, T.S., Gerritz, S.W., Banks, M., O'Connell, J., Traynor, J.R., Alt, A., Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 10830–10835.
12. Busquets-Garcia, A., Soria-Gomez, E., Redon, B., Mackenbach, Y., Vallee, M., Chaouloff, F., Varilh, M., Ferriera, G., Piazza, P.V., Marsciano, G., Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol. Psychiatry., 2017 (advanced online publication).
13. Campos, A.C., Foqaca, M.V., Sonego, A.B., Guimaraes, F.S., Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmaol. Res. 112 (2016), 119–127.
14. 1) allosteric modulators reveals novel mechanism of action. Bri. J. Pharmacol. 170 (2013), 893–907.
15. Christopoulos, A., Kenakin, T., G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002), 323–374.
16. Conn, P.J., Christopoulos, A., Lindsley, C.W., Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug. Discov. 8 (2009), 41–54.
17. Conn, P.J., Lindsley, C.W., Meiler, J., Niswender, C.M., Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat. Rev. Drug. Discov. 13 (2014), 692–708.
18. Dhopeshwarkar, A., Murataeva, N., Makriyannis, A., Straiker, A., Mackie, K., Two janus cannabinoids that are both CB2 agonists and CB1 antagonists. J. Pharmacol. Exp. Ther. 360 (2017), 300–311.
19. DiMarzo, V., Deprés, J.-P., CB1 antagonisats for obesity—what lessons have we learned from rimonabant?. Nat. Rev.Endocrinol 5 (2009), 633–638.
20. 1 receptor allosteric modulator ORG27569 in rats. Pharmacol. Res. Perspect., 2, 2014, e00069.
21. Dror, R.O., Green, H.F., Valant, C., Borhani, D.W., Valcourt, J.R., Pan, A.C., Arlow, D.H., Canals, M., Lane, J.R., Rahmani, R., Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 84 (2013), 295–299.
22. 1 T210 produces active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochem 45 (2006), 5606–5617.
23. ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in Cannabis potency over the last 2 decades (1995-2014). Anal. Curr. data United States. Biol. Psychiatry 79 (2016), 613–619.
24. 1 is blocked by the allosteric ligand Org 27569. J. Biol. Chem. 287 (2012), 33873–33882.
25. Fay, J.F., Farrens, D.L., The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochem 52 (2013), 8286–8294.
26. 1. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 8469–8474.
27. Frank, B., Serpell, M.G., Hughes, J., Matthews, J.N.S., Kapur, D., Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain, randomized, crossover, double blind study. B. M. J. 336 (2008), 199–201.
28. Franks, L.N., Ford, B.M., Madidi, N.R., Penthala, N.R., Crooks, P.A., Prather, P.L., Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: indole quinuclidine analogs. Eur. J. Pharmacol. 737 (2014), 140–148.
29. 1-receptor allosteric modulator-ORG27569. Behav. Pharmacol. 25 (2014), 182–185.
30. Gamage, T.F., Anderson, J.C., Abood, M.,E., CB1 Allosteric modulator ORG27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res. 1 (2016), 272–280.
31. Gentry, P.R., Sexton, P.M., Christopoulos, A., Novel allosteric modulators of G-protein coupled receptors. J. Biol. Chem. 290 (2015), 19478–19488.
32. 1 receptor: structure–activity relationship studies on 1-(4-Chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J. Med. Chem. 57 (2014), 7758–7769.
33. Goblysos, A., Ijzerman, A.P., Allosteric modulation of adenosine receptors. Biochim. Biophy. Acta 1808 (2011), 1309–1318.
34. Gomes, I., Grushko, J.S., Golebiewska, U., Hoogendoorn, S., Gupta, A., Heimann, A.S., Ferro, E.S., Scarlata, S., Fricker, L.D., Devi, L.A., Novel endogenous peptide agonists of cannabinoid receptors. FASEB J. 23 (2009), 3020–3029.
35. Gregory, K.J., Sexton, P.M., Christopoulos, A., Overview of receptor allosterism. Curr. Protoc. Pharmacol. 51 (2010), 1.21.1–1.21.34.
36. 1 cannabinoid receptors. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 20588–20593.
37. Hofer, S.C., Ralvenius, W.T., Gachet, M.S., Fritschy, J., Zeilhofer, H.U., Gertsch, J., Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla. Neuropharmacol 98 (2015), 78–89.
38. 1 receptors with hypophagic effects in rats. Br. J. Pharmacol. 152 (2007), 805–814.
39. Howlett, A.C., Cannabinoid receptor signaling. Handb. Exp. Pharmacol. 168 (2005), 53–79.
40. Howlett, A., Reggio, P.H., Childers, S.R., Hampson, R.E., Ulloa, N.M., Deutsch, D.G., Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br. J. Pharmacol. 163 (2011), 1329–1343.
41. 1. Cell 167 (2016), 750–762.
42. Ignatowska-Jankowska, B.M., Baillie, G.L., Kinsey, S., Crowe, M., Ghosh, S., Owens, R.A., Damaj, I.M., Poklis, J., Wiley, J.L., Zanda, M., Zanato, C., Greig, I.R., Lichtman, A.H., Ross, R.A., A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology 40 (2015), 2948–2959.
43. 1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 143 (2014), 251–256.
44. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., Fallon, M.T., Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom Manag. 39 (2010), 167–179.
45. Kenakin, T.P., Biased signaling and allosteric machines: new vistas and challenges for drug discovery. Br. J. Pharmacol. 165 (2012), 1659–1669.
46. Kenakin, T.P., Miller, L.J., Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62 (2010), 265–304.
47. Khajehali, E., Malone, D.T., Glass, M., Sexton, P.M., Christopoulos, A., Leach, K., Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol. Pharmacol. 88 (2015), 369–379.
48. 1). J. Med. Chem. 57 (2014), 3040–3052.
49. 1. J. Med. Chem. 60 (2017), 1089–1104.
50. Knudsen, L.B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J.T., Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 937–942.
51. Langmead, C., Christopoulos, A., Functional and structural perspectives on allosteric modulation of GPCRs. Curr. Opin. Cell Biol. 27 (2014), 94–101.
52. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Donovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172 (2015), 4790–4805.
53. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Donovan-Wright, E.M., Biased Type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of huntington disease. Mol. Pharmacol. 89 (2016), 364–375.
54. Laprairie, R.B., Kulkarnie, P.M., Deschamps, J.R., Kelly, M.E., Janero, D.R., Cascio, M.G., Stevenson, L.A., Pertwee, R.G., Kenakin, T., Denovan-Wright, E.M., Thakur, G.A., Enantio-specific allosteric modulation of cannabinoid 1 receptor. Chm. Neurosci., 2017, 10.1021/acschemneuro.6b00310.
55. Leo, A., Russo, E., Elia, M., Cannabidiol and epilepsy: rational and therapeutic potential. Pharmacol. Res. 107 (2016), 85–92.
56. Leterrier, C., Bonnard, D., Carrel, D., Rossier, J., Lenkei, Z., Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004), 36013–36021.
57. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkötter, J., Hellmich, M., Koethe, D., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry, 20, 2012, 10.1038/tp.2012.15.
58. Lindsley, C.W., Wiscnoski, D.D., Leister, W.H., O'Brien, J.A., Lemaire, W., Williams, D.L., Burno, M., Sur, C., Kinney, G.G., Doug, J.P., Tiller, P.R., Smith, S., Duggan, M.E., Hartman, G.D., Conn, P.J., Huff, J.R., Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 47 (2004), 5825–5828.
59. Luttrell, L.M., Minireview: more than just a hammer: ligand “bias” and pharmaceutical discovery. Mol. Endocrinol. 28 (2014), 281–294.
60. Mackie, K., Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Tox 46 (2006), 101–122.
61. 1). J. Med. Chem. 56 (2013), 7965–7975.
62. Manzanares, J., Julian, M., Carrascosa, A., Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr. Neuropharmacol. 4 (2006), 239–257.
63. May, L.T., Leach, K., Sexton, P.M., Christopoulos, A., Allosteric modulators of G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 1–51.
64. Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32 (2011), 81–151.
65. Navarro, H.A., Howard, J.L., Pollard, G.T., Carroll, F.I., Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br. J. Pharmacol. 156 (2009), 1178–1184.
66. Neisink, R.J., van Laar, M.W., Does cannabidiol protect against adverse psychological effects of THC?. Front. Psychiatry, 4, 2013, 130.
67. 1 receptor allosteric modulators. Bioorg. Med. Chem. 23 (2015), 2195–2203.
68. 1-dependent catalepsy in mice. Neurosci. Lett. 470 (2010), 33–37.
69. 1 cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 21134–21139.
70. Pertwee, R.G., The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J.Obes 30 (2006), S13–S18.
71. 1 receptor. Mol. Pharmacol. 68 (2005), 1484–1495.
72. 1 receptor. Eur. J. Med. Chem. 121 (2016), 517–529.
73. Reddy, D.S., The utility of cannabidiol in the treatment of refractory epilepsy. Clin. Pharmacol. Ther. 101 (2017), 182–184.
74. Ross, R.A., Allosterism and cannabinoid CB1 receptors: the shape of things to come. Trends Pharmacol. Sci. 28 (2007), 567–572.
75. Russo, E.B., Cannabinoids in the management of difficult to treat pain. Ther. Clin. Risk Manag. 4 (2008), 245–259.
76. Sagar, D.R., Gaw, A.G., Okine, B.N., Woodhams, S.G., Wong, A., Kendall, D.A., Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol. Pain., 5, 2009, 59.
77. 1 cannabinoid receptor. Nature 540 (2016), 602–606.
78. Shore, D.M., Baillie, G.L., Hurst, D.H., Navas, F., Seltzman, H.H., Marcu, J.P., Abood, M.E., Ross, R.A., Reggio, P.H., Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein coupling. J. Biol. Chem., 289, 2014 5828–4.
79. Slivicki, R., Hohmann, A.G., Positive Allosteric Modulation of Cannabinoid CB1 Receptor Signaling Suppresses Chemotherapy-induced Peripheral Neuropathy. 2016, Society for Neuroscience Meeting, San Diego, CA.
80. 1 among different membrane microenvironments. Sci. Rep., 5, 2015, 15453.
81. 1 in a neuronal model. Pharmacol. Res. 99 (2015), 370–376.
82. 1 cannabinoid receptor. J. Mol. Endocrinol. 44 (2010), 75–85.
83. Vallee, M., Vitiello, S., Bellocchio, L., Hebert-Chatelain, E., Monlezun, S., Martin-Garcia, E., Kasanetz, F., Baillie, G.L., Panin, F., Cathala, A., Roullot-Lacarriere, V., Fabre, S., Hurst, D.P., Lynch, D.L., Shore, D.M., Deroche-Garmonet, V., Spampinato, U., Revest, J.M., Maldonado, R., Reggio, P.H., Ross, R.A., Marsicno, G., Piazza, P.V., Pregnenolone can protect the brain from cannabis intoxication. Science 343 (2014), 94–98.
84. Wade, D.T., Robson, P., House, H., Makela, P., Aram, J., A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17 (2003), 21–29.
85. 1 receptor modulation in the cerebellum. Mol. Pharmacol. 79 (2010), 758–767.
86. Wild, C., Cunningham, K.A., Zhou, J., Allosteric modulation of G protein-coupled receptors: an emerging approach of drug discovery. J. Pharmacol. Ther., 2, 2013, 1.
87. Wong, M., Devinsky, O., Thiele, E., Appleton, R., Patel, A., Harden, C., Sommerville, K., Greenwood, S., Morrison, G., A dose ranging safety and pharmacokinetic study of cannabidiol (CBD) in children with Dravet syndrome (GWPCARE1). American Epilepsy Society Annual Meeting www.aesnet.org, 2016.